Stinging insect allergy

---

• 1.
• Donovan GR, Baldo BA, Sutherland S. Molecular cloning and characterisation of a major allergen (Myr p 1) from the venom of the Australian jumper ant. Biochim Biophys Acta 1993; 1171: 272-280.
• 2.
• Stuckey M, Cobain T, Sears M, et al. Bee venom hypersensitivity in Busselton [letter]. Lancet 1982; 2: 41.
• 3.
• Harvey P, Sperber S, Kette F, et al. Bee-sting mortality in Australia. Med J Aust 1984; 140: 209-211.
• 4.
• Douglas RG, Weiner JM, Abramson MJ, O'Hehir RE. Prevalence of severe ant-venom allergy in southeastern Australia. J Allergy Clin Immunol 1998; 101: 129-131.
• 5.
• Reisman RE. Clinical aspects of hymenoptera allergy. In: Levine MI, Lockey RF, editors. Monograph on insect allergy. Pittsburgh: Dave Lambert Associates, 1995: 39-42.
• 6.
• Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81: 1-5.
• 7.
• Golden DBK, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA 1989; 262: 240-244.
• 8.
• Muller UR. Immunotherapy of insect venom allergy - state of the art. ACI Int 1997; 9: 180-184.
• 9.
• Glaspole I, Douglass JA, Czarny D, O'Hehir RE. Stinging insect allergies: assessing and managing. Aust Fam Physician 1997; 26: 1395-1399.
• 10.
• Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78: 76-83.
• 11.
• Douglas RG, O'Hehir RE. Peanut allergy. Education, avoidance and adrenaline are the mainstays of management. Med J Aust 1997; 166: 63-64.
• 12.
• Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992; 90: 335-339.
• 13.
• Thoracic Society of Australia and New Zealand and Australasian Society of Clinical Immunology. Specific allergen immunotherapy for asthma [position statement]. Med J Aust 1997; 167: 540-544.
• 14.
• Dent O. Clinical workforce in internal medicine and paediatrics in Australia, 1997. Fellowship Aff 18: 31-40.
• 15.
• Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-g secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-4194.
• 16.
• Rolland JM, O'Hehir RE. Immunotherapy of allergy: anergy, deletion and immune deviation. Curr Opin Immunol 1998; 10: 640-645.
• 17.
• Muller U, Akdis A, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101: 747-754.